Market Signal Briefing

KBR Inc. (KBR - Free Report) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.37%. A quarter ago, it was expected that this the engineering, construction company would post earnings of $0.88 per share when it actually produced earnings of $0.91, delivering a surprise of +3.41%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

KBR, which belongs to the Zacks Engineering - R and D Services industry, posted revenues of $1.93 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.29%. This compares to year-ago revenues of $1.95 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

KBR shares have lost about 26% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for KBR?While KBR has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for KBR was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.02 on $2.06 billion in revenues for the coming quarter and $3.77 on $8.03 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Engineering - R and D Services is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Amentum Holdings (AMTM - Free Report) , is yet to report results for the quarter ended September 2025. The results are expected to be released on November 25.

This government services company is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of +25.5%. The consensus EPS estimate for the quarter has been revised 6.5% higher over the last 30 days to the current level.

Amentum Holdings' revenues are expected to be $3.61 billion, up 63.1% from the year-ago quarter.

LXP Industrial (LXP - Free Report) came out with quarterly funds from operations (FFO) of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.16 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this real estate investment trust would post FFO of $0.16 per share when it actually produced FFO of $0.16, delivering no surprise.

Over the last four quarters, the company has not been able to surpass consensus FFO estimates.

LXP Industrial, which belongs to the Zacks REIT and Equity Trust - Residential industry, posted revenues of $86.9 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 1.83%. This compares to year-ago revenues of $85.57 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

LXP Industrial shares have added about 17.2% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for LXP Industrial?While LXP Industrial has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for LXP Industrial was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.16 on $88.81 million in revenues for the coming quarter and $0.63 on $353.91 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Residential is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

UMH Properties (UMH - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 3.

This real estate investment trust is expected to post quarterly earnings of $0.25 per share in its upcoming report, which represents a year-over-year change of +4.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

UMH Properties' revenues are expected to be $68.9 million, up 13.6% from the year-ago quarter.

Integra LifeSciences (IART - Free Report) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +25.58%. A quarter ago, it was expected that this medical device maker would post earnings of $0.43 per share when it actually produced earnings of $0.45, delivering a surprise of +4.65%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Integra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $402.06 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 3.07%. This compares to year-ago revenues of $380.83 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Integra shares have lost about 32% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for Integra?While Integra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Integra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.93 on $457.68 million in revenues for the coming quarter and $2.21 on $1.67 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, ClearPoint Neuro, Inc. (CLPT - Free Report) , has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -11.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

ClearPoint Neuro, Inc.'s revenues are expected to be $9.9 million, up 21.9% from the year-ago quarter.

Lakeland Industries (LAKE - Free Report) is a Zacks Rank #1 (Strong Buy) that has a D for Value and a D for Growth. This company makes suits used in clean ups big and small.  Their products range from toxic waste clean up garments to Fireland Fyrepel products that are used for fire and heat protection.  The company also makes special safety gloves and medical woven cloth garments.  Let’s learn more about why this stock is the Bull of the Day.

Description                                              

Lakeland Industries, Inc. engages in the manufacture and sale of safety garments and accessories for the industrial and public protective clothing market. It operates through the Domestic and International geographical segments. The firm's products include disposable protective clothing, chemical protective clothing, woven protective clothing, fire protective gear, heat protective clothing, reflective protective clothing, hand and arm protection, arc or fire-retardant rated rainwear, and fire-retardant protective clothing. The company was founded in April 1982 and is headquartered in Huntsville, AL.

Earnings History                                                         

When I look at a stock, the first thing I do is look to see if the company is beating the number.  This tells me right away where the market’s expectations have been for the company and how management has communicated to the market.  A stock that consistently beats has management communicating expectations to Wall Street that can be achieved.  That is what you want to see.

Lakeland Industries (LAKE ) has missed the Zacks Consensus Estimate in three of the last four quarters. The company most recently posted EPS of $0.36 per share when the Zacks Consensus Estimate was calling for a loss of $0.04.  That 40 cent beat translates into a 1000% positive earnings surprise.

Over the last four quarters the average positive surprise works out to be 106%.

Earnings Estimates Revisions

Earnings estimate revisions is what the Zacks Rank is all about. 

Estimates are moving higher for Lakeland Industries (LAKE - Free Report) .

The full year 2025 has increased from $0.18 to $0.50 over the last 60 days.

2026 has increased from $1.23 to $1.28 over the same time period.

Growth

There is good growth projected for Lakeland Industries (LAKE - Free Report) .  This fiscal year analysts are expecting $213M in revenue which would be good for 27% topline growth.

Next fiscal year, the consensus is calling for $240 M and that would be good for 12.7% sales growth.

Valuation

The valuation for Lakeland Industries (LAKE - Free Report) is compelling in terms of price to book.  I see a price to book multiple of 1.06x which means investors are barely paying a premium over the cost of the assets on hand.  The forward PE if 32x is a little high, but the growth the company is expected to show makes up for that high multiple.  Price to sales comes in at 0.82x which suggests the market doesn’t give the company full credit for each dollar of sales the company posts.  Part of the reason for that is the negative operating margins the company has shown over the last few quarters.

Management to host Investor Conference Call at 8:30 a.m. ET on the same day to discuss results

, /PRNewswire/ -- Ceragon (NASDAQ: CRNT), a leading solutions provider of end-to-end wireless connectivity, announces that it will release its earnings results for the third quarter ended September 30, 2025 on Tuesday, November 11, 2025, before the market opens.

The Company will hold a Zoom webcast at 8:30 a.m. ET that same day to review the results, which will include a Q&A session. Investors may register for the call by clicking here. All relevant access details will be provided upon registration.

For those unable to join the live call, a replay will be available on the Company's website at www.ceragon.com.

About Ceragon

Ceragon (NASDAQ: CRNT) is the global innovator and leading solutions provider of end-to-end wireless connectivity, specializing in transport, access, and AI-powered managed & professional services. Through our commitment to excellence, we empower customers to elevate operational efficiency and enrich the quality of experience for their end users.

Our customers include service providers, utilities, public safety organizations, government agencies, energy companies, and more, who rely on our wireless expertise and cutting-edge solutions for 5G & 4G broadband wireless connectivity, mission-critical services, and an array of applications that harness our ultra-high reliability and speed. Ceragon solutions are deployed by more than 600 service providers, as well as more than 1,600 private network owners, in more than 130 countries. Through our innovative, end-to-end solutions, covering hardware, software, and managed & professional services, we enable our customers to embrace the future of wireless technology with confidence, shaping the next generation of connectivity and service delivery. Ceragon delivers extremely reliable, fast to deploy, high-capacity wireless solutions for a wide range of communication network use cases, optimized to lower TCO through minimal use of spectrum, power, real estate, and labor resources - driving simple, quick, and cost-effective network modernization and positioning Ceragon as a leading solutions provider for the "connectivity everywhere" era.

For more information please visit: www.ceragon.com

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON® is a trademark of Ceragon, registered in various countries. Other names mentioned are owned by their respective holders.

Investor Contact:

Rob Fink
FNK IR
1+646-809-4048

Joey Delahoussaye
FNK IR
1+312-809-1087

[email protected]

Logo - https://mma.prnewswire.com/media/1704355/Ceragon_Networks_Ltd_Logo.jpg

SOURCE Ceragon Networks Ltd.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

October 30, 2025 7:00 AM EDT | Source: PreveCeutical Medical Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 11,375,000 units (each, a "Unit") of the Company at a price of $0.04 per Unit for gross aggregate proceeds of $455,000.

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.06 per Warrant Share for a period of 24 months from the closing of the Second Tranche (the "Second Tranche Closing"), subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.18 or greater on the Canadian Securities Exchange ("CSE") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30th day after the date on which the news release is disseminated (the "Acceleration Right").

In connection with the Second Tranche Closing, the Company paid finders fees to three eligible finders comprised of $29,200 in cash and issued 730,000 finder's Warrant (each, a "Finder's Warrant"). The Finder's Warrant are exercisable into one additional Share at an exercise price of $0.06 per Share for 24 months from the Second Tranche Closing, subject to the Acceleration Right.

The Company intends to use the aggregate gross proceeds of the Second Tranche to pay outstanding payables, for operating expenses and for general working capital purposes.

All securities issued in relation to the Second Tranche are subject to a hold period expiring four months and one day after the Second Tranche Closing, in accordance with applicable securities laws.

The securities issued under the Offering, including those in the Second Tranche, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Second Tranche and the closing of a subsequent tranche of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Second Tranche may not be used as stated in this news release, that the Company may not be able to close a subsequent tranche of the Offering and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272529

WASHINGTON--(BUSINESS WIRE)--FiscalNote Holdings, Inc. (NYSE: NOTE), the leading provider of AI-driven policy and regulatory intelligence solutions, today announced it will report financial results for the Third Quarter ended September 30, 2025, on Thursday, November 6, 2025, immediately following market close. The Company will also conduct a related conference call at 5:00 p.m. ET (U.S.) on that same day. Information regarding how to participate in the conference call is provided below.

Conference Call Information:

LIVE

Via Phone

For the U.S. or Canada, dial 1 (800) 715-9871; for International, dial (646) 307-1963. Enter conference ID 7871199.

Via Webcast

Visit the Investor Relations section of the Company’s website.

REPLAY

Via Phone

For the U.S. or Canada: dial 1 (800) 770-2030; for International: dial (609) 800-9099. Enter conference ID 7871199. (Replay available through Thursday, November 13, 2025).

Via Webcast

Visit the Investor Relations section of the Company’s website. (Webcast is archived indefinitely).

About FiscalNote

FiscalNote (NYSE: NOTE) is the leading SaaS provider of policy and regulatory intelligence. By uniquely combining proprietary AI technology, comprehensive data, and decades of trusted analysis, FiscalNote helps customers manage political and business risk. Since 2013, FiscalNote has pioneered solutions that deliver critical insights, enabling efficient decision making and giving organizations the competitive edge they need. Home to PolicyNote, CQ, Roll Call, VoterVoice, and many other industry-leading products and brands, FiscalNote serves thousands of customers worldwide with global offices in North America, Europe, and Asia. To learn more about FiscalNote and its suite of solutions, visit FiscalNote.com and follow @FiscalNote.

Investors must own AMPG Common stock by the close of Nasdaq trading on Friday, November 7, 2025 to be a Record Date holder

Hauppauge, NY, October 30, 2025 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company” or “AmpliTech”), a leading designer and manufacturer of advanced signal-processing components for satellite, 5G/6G networks, and quantum systems, today announced that it intends to offer to its shareholders and certain warrantholders a dividend in the form of a transferable unit subscription right ( “Unit Rights”) to participate in the unit rights offering.

AmpliTech has an effective Form S-3 base prospectus from which it intends to offer these securities registered with the Securities and Exchange Commission (the “SEC”) for a proposed rights offering in which it plans to distribute to (a) stockholders and (b) certain warrantholders two transferable Unit Rights to purchase up to the maximum of 8,000,000 units at $4.00 per unit. Each unit will consist of one share of common stock (the “Common Shares”) and two short-term rights to purchase additional Common Shares.

Under the rights offering, each stockholder and certain warrant holders as of the record date will receive, as a dividend, at no charge, two Unit Rights for each (a) Common Share and (b) each Common Share subject to a Warrant owned on the record date. The distribution of the Unit Rights will occur on or around the record date. The record date for the distribution of the Unit Rights, the expiration dates for the Unit Rights and related short-term rights, and related pricing information will be included in the final prospectus.

Holders who fully exercise their Unit Rights will be entitled to oversubscribe for additional units, if available, that are not purchased by other right holders, subject to potential pro rata allocation of those over-subscription units for which they subscribe in proportion to the total number of over-subscription units.

AmpliTech intends to use the net proceeds of the rights offering to scale domestic manufacturing and operations; advance R&D and product commercialization; deepen vertical integration and supply-chain resilience; engage in strategic partnerships; and support corporate growth initiatives; and for working capital and general corporate purposes. The Company recommends that current shareholders and certain warrant holders notify their broker or financial advisor about the upcoming rights offering to ensure their ability to participate.

The expected calendar for the rights offering is as follows:

 DatesOwnership date (last day to buy AMPG to become Record date holder)November 7, 2025Record dateNovember 10, 2025Commencement dateNovember 11, 2025 UNIT RIGHTS Deadline for delivery of subscription and payment of unit subscription priceDecember 10, 2025Expiration date for Subscription RightsDecember 10, 2025Extension period (if any)January 9, 2026   SERIES RIGHTS Series A Rights Subscription Price of $5.00 per share Deadline for delivery of subscription and payment of exercise priceJuly 18, 2026Expiration date for Series A RightsJuly 18, 2026 Series B Rights Subscription Price of $6.00 per share Deadline for delivery of subscription and payment of exercise priceNovember 20, 2026Expiration date for Series B RightsNovember 20, 2026
Please contact our information agent MacKenzie Partners, Inc. if you have questions about the rights offering or need copies of the prospectus at [email protected].

AmpliTech has engaged Moody Capital Solutions, Inc. to act as dealer-manager for the rights offering. Broker dealers, registered investment advisors and institutions may contact Moody at [email protected].

AmpliTech reserves the right to terminate the proposed rights offering at any time prior to the expiration date and for any reason. A prospectus relating to these securities will be filed with the SEC. This announcement shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Securities of AmpliTech are NSMIA exempt. A security that is NSMIA exempt is classified as a “covered security” under the National Securities Markets Improvement Act of 1996 and is therefore exempt from state-level registration and regulation, subject only to federal oversight through the SEC. The rights offering will be made only by means of a prospectus.

About AmpliTech Group, Inc.

AmpliTech Group, Inc., is comprised of five divisions, AmpliTech Inc., Specialty Microwave, Spectrum Semiconductors Materials, AmpliTech Group Microwave Design Center, and AmpliTech Group True G Speed Services, is a leading designer, developer, manufacturer, and distributor of cutting-edge radio frequency (RF) microwave components and 5G network solutions. Serving global markets including satellite communications, telecommunications (5G & IoT), space exploration, defense, and quantum computing, AmpliTech Group is committed to advancing technology and innovation. For more information, please visit our website at www.amplitechgroup.com or amplitech5G.com.

About Moody Capital Solutions, Inc.

Moody Capital Solutions, Inc. has cultivated and actively maintains deep relationships across a wide network of institutional investors, top-tier law firms, and investor relations specialists. These connections empower it to deliver unmatched advisory services and seamless transaction execution. At Moody Capital, every client engagement is led directly by senior bankers—from strategy to closing. Unlike larger firms, it does not delegate execution to junior staff. Moody Capital is a relationship-driven investment bank committed to delivering high-touch, high-quality results. Moody Capital senior bankers collectively have more than 150 years of investment banking experience. Moody Capital senior bankers have worked at some of the leading large-cap and small-cap investment banks in the U.S.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things, that the Company will close and be successful in raising capital in connection with the rights offering. The words “may” “would” “will” “expect” “estimate” “anticipate” “believe” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, which are available on our website and with the SEC at www.sec.gov. We undertake no obligation to update, and we do not have a policy of updating or revising these forward-looking statements, except as required by applicable law.

Contacts:

Corporate Social Media
X: @AmpliTechAMPG 
Instagram: @AmpliTechAMPG
Facebook: AmpliTechInc
LinkedIn: AmpliTech Group Inc

Company Contact:
Jorge Flores
Tel: 631-521-7831
[email protected]

Investor Relations Contact:
Kirin Smith
[email protected]

Source: AmpliTech Group 

Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo Purchase Licensing Rights, opens new tab

CompaniesOct 30 (Reuters) - Bristol Myers Squibb

(BMY.N), opens new tab beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs.

Bristol Myers also raised its full-year revenue forecast, reflecting optimism that its portfolio of recently launched drugs will plug a multibillion-dollar revenue gap from patent expirations that open several best-selling drugs to competition. CEO Christopher Boerner has also aggressively pursued acquisitions and partnerships to fill Bristol Myers' pipeline.

Sign up here.

For the third quarter, Bristol Myers posted revenue of $12.22 billion, beating analysts' average estimate of $11.8 billion, according to data compiled by LSEG.

On an adjusted basis, the company earned $1.63 per share, compared with estimates of $1.51 per share.

Sales of its top cancer immunotherapy, Opdivo, rose 7% to $2.53 billion, and the newer subcutaneously injected version of the drug added another $67 million. That compares with analyst expectations of $2.2 billion.

Bristol Myers Chief Commercialization Officer Adam Lenkowsky said in an interview that the company still expects to convert 30% to 40% of its Opdivo sales to the subcutaneous version before the drug's patent expires.

Sales of blood thinner Eliquis, which Bristol Myers shares with Pfizer

(PFE.N), opens new tab, jumped 25% to $3.75 billion, compared with Wall Street estimates of $3.4 billion.

Revenue from the company's "growth portfolio," which includes Opdivo and new products like heart drug Camzyos, rose 18% to $6.9 billion, helping to offset a 59% plunge in sales of blood cancer treatment Revlimid, its one-time top-selling drug, to $575 million.

Bristol Myers now expects full-year earnings in the range of $47.5 billion to $48 billion, up from its previous forecast of $46.5 billion to $47.5 billion.

Bristol has been contending with a steep revenue decline from Revlimid, which raked in nearly $13 billion in 2021 but only $5.8 billion last year due to generic competition. Some of its other cancer drugs such as Pomalyst, Sprycel and Abraxane are contending with the same issue.

The company is also under pressure from the Trump administration to lower drug prices. President Donald Trump has unveiled deals in recent weeks with Pfizer Inc

(PFE.N), opens new tab and UK-based drugmaker AstraZeneca

(AZN.L), opens new tab under which the companies will sell some medicines at a discount to Medicaid, the government health plan for low-income people, in exchange for tariff relief.

"We continue to engage with the administration," Lenkowsky said.

Reporting by Michael Erman; Editing by Leslie Adler

Our Standards: The Thomson Reuters Trust Principles., opens new tab

-

IonQ executives highlight the company’s latest quantum advancements underscoring progress around the UK's collaborative quantum strategy

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation in the 2025 UK National Quantum Technologies Showcase, taking place on November 7th at the Business Design Centre in London. Organized by Innovate UK in collaboration with the Engineering and Physical Sciences Research Council (EPSRC) and the UK National Quantum Technologies Programme (UKNQTP), it is one of the largest quantum events in the UK, convening more than 2,000 stakeholders across government, academia, and industry.

“We are delighted to demonstrate our latest advancements in quantum computing innovation at the UK Quantum Showcase this year. The UK has long held a leading position in quantum technologies due to its world-class science and research base,” said Dr. Chris Ballance, President of Quantum Computing at IonQ and co-founder of Oxford Ionics. “The strength of the UK’s technological leadership helped us achieve the highest-performing quantum platform available on the market."

IonQ’s presence at the showcase follows a landmark year for the company in the UK, including the designation of Oxford as IonQ’s EMEA headquarters, its acquisition of Oxford Ionics, and the delivery of Quartet, a quantum computing testbed for the UK’s National Quantum Computing Centre (NQCC). These milestones reinforce IonQ’s role as a key player in advancing the UK’s national quantum strategy as it accelerates the commercial use of quantum technologies.

IonQ will host booth #52 where participants will explore the company’s latest quantum innovations.

About IonQ

IonQ, Inc. [NYSE: IONQ] is the world’s leading quantum company delivering solutions to solve the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results.

The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ’s advancements in quantum networking also position the company as a leader in building the quantum internet.

The company’s innovative technology and rapid growth were recognized in Fortune Future 50, Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature are intended to identify forward-looking statements. These statements include those related to the scalability, fidelity, efficiency, viability, accessibility, effectiveness, reliability, performance, speed, and commercial-readiness of IonQ’s offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ’s ability to deliver, and customers’ ability to generate, value from IonQ’s offerings; IonQ’s ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ’s ability to effectively integrate its acquisitions of Oxford Ionics Limited; changes in laws and regulations affecting IonQ’s patents; and IonQ’s ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

More News From IonQ, Inc.

Back to Newsroom

October 30, 2025 07:05 ET

 | Source:

Zhihu Inc.

BEIJING, China, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it will report its unaudited financial results for the quarter ended September 30, 2025 before the U.S. market opens on November 25, 2025.

The Company’s management will host a conference call at 6:00 A.M. U.S. Eastern Time on Tuesday, November 25, 2025 (7:00 P.M. Beijing/Hong Kong Time on Tuesday, November 25, 2025) to discuss the results.

All participants wishing to join the conference call must pre-register online using the link provided below. Once the pre-registration has been completed, each participant will receive a set of dial-in numbers and a unique access PIN which can be used to join the conference call.

Registration Link: https://register-conf.media-server.com/register/BId01f39d00a68420ba15e28d3dc711d2d

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.zhihu.com.

About Zhihu Inc.

Zhihu Inc. (NYSE: ZH; HKEX: 2390) is a leading online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Since the initial launch in 2010, Zhihu has grown into the largest Q&A-inspired online content community in China. For more information, please visit https://ir.zhihu.com.

For investor and media inquiries, please contact:

Zhihu Inc.
Email: [email protected]

Christensen Advisory
Roger Hu
Tel: +86-10-5900-1548
Email: [email protected]

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales
Received 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN
Reported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN and continued high patient compliance in PNH
SYFOVRE® (pegcetacoplan injection) total injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $151 million
Cash and cash equivalents of $479 million as of September 30, 2025; existing cash expected to be sufficient to fund business to sustainable profitability
Management to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.

“The third quarter was marked by strong execution and meaningful progress across our commercial and development portfolio. We were thrilled to receive our third regulatory approval in just four years, introducing a first-in-class C3 therapy for patients with C3G and primary IC-MPGN, many of whom previously had no available treatment options. The positive reception from the nephrology community reflects recognition of EMPAVELI’s compelling efficacy and safety profile, and strengthens our confidence in its potential to become the treatment of choice for patients,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis. “At the same time, SYFOVRE continues to lead the geographic atrophy market and deliver a steady, durable revenue stream that supports our long-term growth ambitions. Combined with our strong financial position, these achievements enable us to enter the fourth quarter and 2026 with a solid foundation and clear momentum for continued growth.”

Third Quarter 2025 Business Highlights and Upcoming Milestones

Maximizing EMPAVELI’s impact in rare diseases

Recorded $26.8 million in EMPAVELI U.S. net product revenue for the third quarter 2025.C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN): On July 28, 2025, EMPAVELI was approved by the U.S. Food and Drug Administration (FDA) as the first treatment for C3G and primary IC-MPGN for patients 12 and older. Approval was based on the trifecta of positive outcomes in the Phase 3 VALIANT study including a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits as measured by C3 staining, compared to placebo.Launch is underway with 152 patient start forms received as of September 30, 2025. This number includes approximately 50 patients from the Company’s early access program who are in the process of transitioning to commercial product.Sobi, the Company’s ex-U.S. commercialization partner, expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its indication extension application for Aspaveli (the brand name for EMPAVELI outside the U.S.) in C3G and primary IC-MPGN before year-end 2025.Seven abstracts were accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week, including new 52-week data from the Phase 3 VALIANT study that reinforce the robust and sustained efficacy profile of EMPAVELI in C3G and primary IC-MPGN. Paroxysmal nocturnal hemoglobinuria (PNH): The Company continues to see high patient compliance rates of 97%. Focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF): The Company expects to initiate two pivotal studies by year-end 2025, one in FSGS and one in DGF, two rare kidney diseases with significant complement pathway involvement and no approved therapies. Transforming the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

SYFOVRE: Generated $150.9 million in SYFOVRE U.S. net product revenue in the third quarter of 2025 Total injections grew 4% quarter-over-quarter.SYFOVRE remains the market leader in GA with total market share exceeding an estimated 60% and 52% of new patient starts during the quarter.Utilization of SYFOVRE free goods remained elevated during the quarter and impacted revenue by approximately $15 million.Delivered approximately 101K SYFOVRE doses to physician offices, including ~86K commercial doses and ~15K free goods doses. The Phase 2 study of SYFOVRE + APL-3007, a potential next generation treatment aimed at comprehensively blocking complement activity in the retina and choroid, is ongoing.
Business Update

Apellis and Sobi announced a capped royalty purchase agreement in July in which Apellis will receive up to $300 million in exchange for 90% of Apellis’ future ex-U.S. royalties for Aspaveli. Per the companies’ 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties.Under the terms of the royalty purchase agreement, Sobi acquired 90% of Apellis’ ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis is also eligible for up to $25 million in milestone payments upon EMA approval of Aspaveli for C3G and IC-MPGN.The agreement is subject to defined caps tied to Aspaveli’s performance. Sobi retains 90% of ex-U.S. royalties until these caps are achieved, after which 100% of all ex-U.S. royalties revert to Apellis. Third Quarter 2025 Financial Results

Total Revenue

Total revenue was $458.6 million for the third quarter of 2025, which consisted of $150.9 million of SYFOVRE U.S. net product revenue, $26.8 million of EMPAVELI U.S. net product revenue, the $275.0 million upfront payment from Sobi in connection with the Aspaveli royalty purchase agreement, and $5.8 million in licensing and other revenue associated with the Sobi collaboration. Total revenue was $196.8 million for the third quarter of 2024, which consisted of $152.0 million of SYFOVRE U.S. net product revenue, $24.6 million in EMPAVELI U.S. net product revenue, and $20.3 million in licensing and other revenue associated with the Sobi collaboration.

Cost of Sales

Cost of sales was $24.5 million for the third quarter 2025, compared to $33.6 million for the same period in 2024. The decrease in cost of sales was primarily driven by lower volumes of product supplied to Sobi, a decrease in expenses incurred related to excess, obsolete or scrapped inventory and a decrease due to costs incurred in connection with cancellable purchase commitments. The decreases were partially offset by a higher volume from commercial sales and product provided under our patient assistance programs.

R&D Expenses

R&D expenses were $68.2 million for the third quarter of 2025, compared to $88.6 million for the same period in 2024. The decrease in R&D expenses was primarily driven by lower program-specific and non-program-specific external costs, and lower compensation and related personnel costs.

Selling, General and Administrative (SG&A) Expenses

SG&A expenses were $142.7 million for the third quarter of 2025, compared to $122.0 million for the same period in 2024. The increase in SG&A was primarily driven by higher general commercial activities, personnel costs and general and administrative expenses, including office expenses, travel expenses, insurance expenses, professional and consulting fees, and other expenses, partially offset by lower personnel costs and lower factoring fees.

Net Income

Apellis reported a net income of $215.7 million for the third quarter 2025, driven by the one-time $275.0 million upfront payment from Sobi in connection with the Aspaveli royalty purchase agreement. This compared to a net loss of $57.4 million for the same period in 2024.

Cash

As of September 30, 2025, Apellis had $479.2 million in cash and cash equivalents, compared to $411.3 million in cash and cash equivalents as of December 31, 2024. Based on its strong cash position, the Company elected to discontinue factoring its receivables during the quarter. Apellis now carries the incremental $80.6 million in receivables from the first three quarters of the year on its balance sheet and expects to realize cost savings of approximately $4.8 million on a go-forward annual basis. The Company continues to expect that its cash, combined with expected product revenues, will fund the business to profitability.

Conference Call and Webcast

Apellis will host a conference call and webcast to discuss its third quarter 2025 financial results and business highlights today, October 30, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the Company’s website. A replay of the webcast will be available for 90 days following the event.

About SYFOVRE® (pegcetacoplan injection)

SYFOVRE® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy secondary to age-related macular degeneration. By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States and Australia.

About EMPAVELI®/Aspaveli® (pegcetacoplan)

EMPAVELI®/Aspaveli® (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. It is the first treatment approved in the United States for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. EMPAVELI is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally, and is under investigation for other rare diseases.

About the Apellis and Sobi Collaboration

Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialization. Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.

U.S. Important Safety Information for SYFOVRE® (pegcetacoplan injection)

CONTRAINDICATIONS

SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.
WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Retinal Vasculitis and/or Retinal Vascular Occlusion Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay. Neovascular AMD In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration. Intraocular Inflammation In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE. Increased Intraocular Pressure Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed. ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.
Please see full Prescribing Information for more information.

U.S. Important Safety Information for EMPAVELI® (pegcetacoplan)

BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, unless the risks of delaying therapy with EMPAVELI outweigh the risks of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
Patients receiving EMPAVELI are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.
Because of the risk of serious infections caused by encapsulated bacteria, EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.

CONTRAINDICATIONS

Hypersensitivity to pegcetacoplan or to any of the excipientsFor initiation in patients with unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

EMPAVELI, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EMPAVELI treatment is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria.

Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of EMPAVELI, according to the most current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.

Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI is available only through a restricted program under a REMS.

EMPAVELI REMS

EMPAVELI is available only through a restricted program under a REMS called EMPAVELI REMS, because of the risk of serious infections caused by encapsulated bacteria. Notable requirements of the EMPAVELI REMS include the following:

Under the EMPAVELI REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, prescribe antibacterial drug prophylaxis if patients’ vaccine status is not up to date and treatment must be started urgently, and provide instructions to always carry the Patient Safety Card both during treatment, as well as for 2 months following last dose of EMPAVELI. Pharmacies that dispense EMPAVELI must be certified in the EMPAVELI REMS and must verify prescribers are certified.

Further information is available at www.empavelirems.com or 1-888-343-7073.

Infusion-Related Reactions

Systemic hypersensitivity reactions (eg, facial swelling, rash, urticaria, pyrexia) have occurred in patients treated with EMPAVELI, which may resolve after treatment with antihistamines. Cases of anaphylaxis leading to treatment discontinuation have been reported. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Monitoring Paroxysmal Nocturnal Hemoglobinuria (PNH) Manifestations after Discontinuation of EMPAVELI

After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests

There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS

Most common adverse reactions in adult patients with PNH (incidence ≥10%) were injection site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, pain in extremity, hypokalemia, fatigue, viral infection, cough, arthralgia, dizziness, headache, and rash.

Most common adverse reactions in adult and pediatric patients 12 years of age and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) (incidence ≥10%) were injection-site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea.

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential

EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the results of the Company’s clinical trials for EMPAVELI, SYFOVRE, or any of its future products will warrant regulatory submissions to the FDA or equivalent foreign regulatory agencies; whether systemic pegcetacoplan will receive approval from foreign regulatory agencies for C3G and primary IC-MPGN; rate and degree of market acceptance and clinical utility of EMPAVELI, SYFOVRE and any future products for which we receive marketing approval will impact our commercialization efforts; whether the Company’s clinical trials will be completed when anticipated; whether results obtained in clinical trials will be indicative of results that will be generated in future clinical trials or in the real world setting; whether the period for which the Company believes that its cash resources will be sufficient to fund its operations; and other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Tracy Vineis
[email protected]
617.420.4839

Investor Contact:
Eva Stroynowski
[email protected]
617.938.6229

APELLIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Amounts in thousands, except per share amounts)         September 30, December 31,    2025   2024  Assets     Current assets:     Cash and cash equivalents $479,171  $411,290  Accounts receivable, net  345,538   264,926  Inventory  122,819   81,404  Prepaid assets  31,560   18,368  Restricted cash  1,430   1,322  Other current assets  10,158   11,644  Total current assets  990,676   788,954  Non-current assets:     Right-of-use assets  19,720   16,083  Property and equipment, net  1,927   2,952  Long-term inventory  40,909   75,713  Other assets  5,491   1,349  Total assets $1,058,723  $885,051  Liabilities and Stockholders' Equity     Current liabilities:     Accounts payable $38,602  $38,572  Accrued expenses  140,322   140,184  Convertible senior notes  93,581   —  Current portion of lease liabilities  7,022   6,753  Total current liabilities  279,527   185,509  Long-term liabilities:     Long-term credit facility  361,091   359,489  Convertible senior notes  —   93,341  Lease liabilities  13,680   10,201  Other liabilities  3,257   7,972  Total liabilities  657,555   656,512  Commitments and contingencies (Note 11)     Stockholders' equity:     Preferred stock, $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at September 30, 2025 and December 31, 2024  —   —  Common stock, $0.0001 par value; 200,000 shares authorized at September 30, 2025 and December 31, 2024; 126,500 shares issued and outstanding at September 30, 2025, and 124,495 shares issued and outstanding at December 31, 2024  12   12  Additional paid-in capital  3,357,583   3,267,201  Accumulated other comprehensive loss  (2,400)  (3,308) Accumulated deficit  (2,954,027)  (3,035,366) Total stockholders' equity  401,168   228,539  Total liabilities and stockholders' equity $1,058,723  $885,051         APELLIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) (Unaudited) (Amounts in thousands, except per share amounts)           For the Three Months Ended September 30, For the Nine Months Ended September 30,   2025   2024   2025   2024   (Unaudited) (Unaudited) Revenue:        Product revenue, net$177,755  $176,571  $499,042  $518,782  Licensing and other revenue 280,823   20,259   304,827   50,057  Total revenue: 458,578   196,830   803,869   568,839  Operating expenses:        Cost of sales 24,531   33,557   72,517   76,867  Research and development 68,186   88,569   221,621   251,216  Selling, general and administrative 142,678   121,984   403,162   379,571  Operating expenses: 235,395   244,110   697,300   707,654  Net operating income/(loss) 223,183   (47,280)  106,569   (138,815) Loss on extinguishment of development liability —   —   —   (1,949) Interest income 4,376   2,889   9,641   9,377  Interest expense (11,279)  (12,532)  (33,480)  (28,857) Other income/(expense), net 37   70   18   (405) Net income/(loss) before taxes 216,317   (56,853)  82,748   (160,649) Income tax expense 602   592   1,409   876  Net income/(loss)$215,715  $(57,445) $81,339  $(161,525) Other comprehensive income/(loss):        Unrealized gain on pension benefits 137   —   137   —  Foreign currency translation 32   222   771   402  Total other comprehensive income 169   222   908   402  Comprehensive income/(loss), net of tax$215,884  $(57,223) $82,247  $(161,123)          Net income/(loss) per share        Basic earnings per share$1.71  $(0.46) $0.65  $(1.31) Diluted earnings per share$1.67  $(0.46) $0.65  $(1.31) Weighted-average shares used in calculating:        Basic earnings per share 126,424   124,234   125,971   123,698  Diluted earnings per share 130,067   124,234   129,653   123,698           

October 30, 2025 07:05 ET

 | Source:

Cartesian Therapeutics, Inc.

FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company’s common stock with an exercise price of $8.85, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. On October 29, 2025, the Company issued to another employee an option to purchase an aggregate of 2,650 shares of the Company’s common stock with an exercise price of $8.20, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The first employee’s option vests as to 25% on October 27, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 27, 2029. The second employee’s option vests as to 25% on October 29, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 29, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
[email protected]

Media Contact:
David Rosen
Argot Partners
[email protected]

Cadence Design Systems NASDAQ: CDNS is a dominant player in a vital part of the semiconductor industry. It provides electronic design automation (EDA) software, which is critical for designing semiconductors.

Jerónimo Martins, SGPS, S.A. (OTCPK:JRONY) Q3 2025 Earnings Call October 30, 2025 5:00 AM EDT

Company Participants

Ana Virgínia - Chief Financial Officer

Conference Call Participants

William Woods - Sanford C. Bernstein & Co., LLC., Research Division
José Rito - Banco BPI, S.A., Research Division
António Seladas - A|S Independent Research

Presentation

Operator

Good day, and welcome to the Jerónimo Martins First 9 Months 2025 Results Conference Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Ms. Ana Luisa Virginia , Chief Financial Officer of Jerónimo Martins Group. Please go ahead, madam.

Ana Virgínia
Chief Financial Officer

Thank you, Sharon. Good morning, ladies and gentlemen, and thank you for joining this call dedicated to our first 9 months results. As usual, in our corporate website, you can find the results release, a slide presentation and a fact sheet for the period.

The first 9 months of 2025 continue to be defined by the ongoing global geopolitical uncertainty that is also shaping consumer sentiment and fostering a more cautious value-driven approach among shoppers. Against this challenging context, price remains at the heart of our strategy across all banners. Every team worked hard to uphold our promise of price leadership and to create an attractive quality assortment, securing customer preference and driving sales growth.

The reinforced commitment to cost discipline, operational efficiency and productivity paid off and ensure that EBITDA margins remained robust despite the tough combination of low basket inflation with high cost inflation in extremely competitive backdrops. Meanwhile, our ambitious CapEx program is being executed as planned, reaching EUR 816 million in the period with the opening of 274 new stores and the renovation of 170 locations.

The balance sheet kept its robustness, closing September with a net cash position, excluding capitalized leases

Recommended For You

HomeInvestingCurrenciesThe dollar index’s decline was arrested in July. It gas been steadily strengthening since.Published: Oct. 30, 2025 at 7:07 a.m. ET

Since mid-July the dollar has been enjoying a steady recovery — with implications for risk assets. Photo: Getty ImagesThere are multiple explanations of why the downtrend in the U.S. dollar has been broken, but the upshot for investors is clear: A rebound in the dollar reduces risk appetite, removes a tailwind for S&P 500 SPX earnings growth, and detracts from the bull argument for gold and the precious-metals complex as a whole.

Despite all the talk of devaluation and de-dollarization, the U.S. currency has demonstrated remarkable resilience since the height of summer, when the dollar index DXY bottomed around 96. Since then, it’s recovered about 3%, and recent developments suggest a breakthrough of the psychologically important 100 level is imminent.

Onex and AIG to acquire Convex, a leading specialty property and casualty (re)insurer that has delivered industry leading growth and strong underwriting profitability, for $7 billion.Onex to own 63% of Convex, AIG to own 35%, with the balance owned by the Convex management team. AIG to acquire a 9.9% equity stake in Onex and will commit $2 billion to Onex’ private equity and credit strategies over the next three years.Transaction leverages Onex’ knowledge of Convex and deep expertise in the insurance ecosystem, where Onex has delivered strong historical investment performance. 
TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Onex Corporation (“Onex”) today announced a transformational investment and new strategic relationship to accelerate growth and drive enterprise value creation. The benefits to Onex include:

The acquisition of a market leading specialty property and casualty insurance and reinsurance business with a proven management team that is positioned for continued strong growth. Onex was a founding investor in Convex Group Limited (“Convex”) in 2019 through Onex Partners V and has worked closely with Stephen Catlin, Paul Brand and the Convex management team to build the business into a highly successful, fast growing and profitable organization.A strategic investment by American International Group, Inc. (“AIG”), one of the world’s leading insurance companies, to acquire a 9.9% stake in Onex. AIG will invest $2 billion of new fee generating assets under management in Onex’ private equity and credit strategies, consistent with its investment guidelines.A more efficient future deployment of Onex’ balance sheet, with continued flexibility for deployment into core areas of expertise, to drive strong long-term investing capital growth.
“Today’s announcement is a logical and foundational step forward for Onex,” said CEO, Bobby Le Blanc. “With these transactions, we are bolstering our already significant position in the insurance sector, securing the support of one of the world’s largest insurers, accelerating profitability of our asset management business and facilitating future growth in our investing capital.”

Transaction Overview

Onex and AIG have entered into an agreement to jointly acquire the entire interest held by Onex Partners V and its co-investors in Convex.

Following the acquisition, Onex and AIG will own approximately 63% and 35%, respectively, of Convex, with the remainder held by the Convex management team. The acquisition values Convex at a $7 billion equity valuation, representing 1.9x Q3 2025 tangible book value.

Stephen Catlin, Paul Brand and the Convex management team founded Convex in 2019 as a de novo insurer in partnership with capital provided by Onex Partners V and its co-investors. Since that time, Convex has rapidly grown into a leading specialty property and casualty (re)insurer with:

Up to $6 billion of expected gross premium written in 2025,25% compound annual growth in gross premium written over the last three years, and 18% average return on equity over the past three years.
The Convex management team will retain a significant economic interest in the business, ensuring strong ongoing alignment with Onex and AIG. A portion of Convex’s investment portfolio is currently allocated to Onex-managed funds, and that is expected to increase over time.

In connection with the transaction, AIG has agreed to subscribe for a 9.9% interest in Onex’ subordinate voting shares, concurrent with the closing of the Convex acquisition, for proceeds totalling approximately $0.6 billion. AIG will also make capital commitments of $2 billion to strategies managed by Onex over a three-year period, driving a significant benefit to Onex’ fee-related earnings.

AIG will enter into an investor rights agreement that, among other things, includes a minimum three-year lock-up on the shares acquired, customary standstill provisions and the right to nominate a director to Onex’ board and who will be mutually agreed upon by Onex and AIG. Onex intends to use the proceeds from the AIG subscription to fund the acquisition.

“With AIG and Convex, two outstanding and world-class organizations, we are ready to enter a new phase of growth and innovation that will bring value to all stakeholders,” added Mr. Le Blanc. “We strongly believe that the expertise and capabilities across all three organizations are truly greater than the sum of the parts.”

Peter Zaffino, Chairman & CEO, AIG commented: “With Onex Corporation, Convex’s primary shareholder, we are building a strategic relationship with an outstanding team, led by CEO Bobby Le Blanc, that has significant experience investing in highly specialized insurance assets. I am pleased that Onex has committed to increasing its ownership share of Convex, preserving Convex’s independence for the long-term. AIG will also benefit from preferred access to Onex’ world-class investment funds, and I look forward to working with Bobby and his talented team as they continue to make strategic investments in various sectors.”

Stephen Catlin, executive chair of Convex Group, said: “In six years, the team at Convex has built an extraordinary business. We have become a major player in global specialty insurance and reinsurance, with annual premium income up to $6 billion and operations in a range of global jurisdictions. We’ve known Peter Zaffino for over 20 years in numerous leadership roles. We greatly admire the contribution he has made to the industry as a whole and, together with the outstanding team he has built at AIG, the successful execution of his strategic vision, positioning AIG for growth and delivering attractive risk adjusted returns for AIG shareholders. This transaction secures the long-term independence of Convex and presents a range of exciting strategic opportunities. We would like to thank our founding shareholders, including Onex, for their unwavering support in establishing and growing the business, and our other supporters within the insurance market. Without them we would not be where we are today.”

Paul Brand, CEO of Convex Group, added: “This is a hugely exciting development for Convex. The Convex team have worked incredibly hard over the last six years to build a world-renowned insurance company, and we see this transaction as the start of the next chapter in our journey. We are delighted to continue our productive partnership with Onex, and that they have decided to make this considerable investment from their own balance sheet. We are also excited to begin a new relationship with AIG. This transaction positions us better than ever to service our clients and brokers, and take advantage of future market opportunities.”

Financial Consideration

Pursuant to the acquisition, Onex will acquire a 63% equity stake in Convex for approximately $3.8 billion. Onex intends to roll over its existing interest in Convex of $0.7 billion, with the remainder financed through $1.5 billion of cash on Onex’ balance sheet and pending asset sales, $1.0 billion of debt financing secured on existing private equity and credit assets, and $0.6 billion of equity financing proceeds from the AIG subscription.

Following the completion of all transactions, Convex is expected to account for 42% of Onex’ investing capital and become a key contributor to future shareholder value creation.

The transaction is expected to close in the first half of 2026, subject to customary regulatory approvals.

Additional Information

A presentation with additional information on today’s announcement is available on the home page of the Onex website at www.onex.com.

As a reminder, Onex will release its third quarter 2025 results on the morning of Friday, November 7th, followed by a live webcast at 11:00 a.m. ET to discuss the third quarter results and this transaction. A link to the webcast and on-line replay will be available on Onex’ website at www.onex.com.

Onex was advised by Goldman Sachs & Co. LLC as lead financial adviser and Latham & Watkins and Torys as legal advisers on the transaction.

About Onex

Onex invests and manages capital on behalf of its shareholders and clients across the globe. Formed in 1984, we have a long track record of creating value for our clients and shareholders. Our investors include a broad range of global clients, including public and private pension plans, sovereign wealth funds, banks, insurance companies, family offices and high-net-worth individuals. In total, Onex has approximately $55.9 billion in assets under management, of which $8.4 billion is Onex’ own investing capital.

With offices in Toronto, New York, New Jersey and London, Onex and its experienced management teams are collectively the largest investors across Onex’ platforms. Onex is listed on the Toronto Stock Exchange under the symbol (TSX:ONEX).

For more information on Onex, visit its website at www.Onex.com. Onex’ security filings can also be accessed at www.sedarplus.ca.

About Convex

Convex is an international specialty insurer and reinsurer focused on complex specialty risks across a diverse range of business lines. Convex occupies a unique position in the insurance industry combining unrivalled experience, reputation and a legacy free balance sheet.

Convex operates out of London, Bermuda, Luxembourg and New Jersey. The company has a ‘A’ (Excellent) A.M. Best rating and an ‘A’ S&P rating.

For additional information, visit www.convexin.com.

About AIG

AIG, Inc. (NYSE:AIG) is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals in more than 200 countries and jurisdictions protect their assets and manage risks through AIG operations, licenses and authorizations as well as network partners.

For additional information, visit www.aig.com.

Forward-Looking Statements

This press release may contain, without limitation, statements concerning possible or assumed future operations, performance or results preceded by, followed by or that include words such as “believes”, “expects”, “potential”, “anticipates”, “estimates”, “intends”, “plans” and words of similar connotation, which would constitute forward-looking statements. The forward-looking statements in this news release include statements regarding Onex Corporation and AIG, Inc.’s acquisition of Onex Partners V’s interest in the Convex Group, AIG Inc.’s subscription for Onex shares, AIG, Inc.’s capital commitments and the entering into of the investor rights agreement.

By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Onex Corporation and AIG, Inc.’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Onex Corporation and AIG, Inc., including, without limitation, the Acquisition and the AIG Investment will be completed on the terms currently contemplated, the Acquisition and the AIG Investment will be completed in accordance with the timing currently expected, all conditions to the completion of the Acquisition will be satisfied or waived and the purchase agreement will not be terminated prior to the completion of the Acquisition.

Forward-looking statements are not guarantees. The reader should not place undue reliance on forward-looking statements and information because they involve significant and diverse risks and uncertainties that may cause actual operations, performance, or results to be materially different from those indicated in these forward-looking statements. Except as may be required by Canadian securities law, Onex is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. These cautionary statements expressly qualify all forward-looking statements in this press release.

Non-GAAP Financial Measures

This press release contains non-GAAP financial measures which have been calculated using methodologies that are not in accordance with IFRS Accounting Standards. The presentation of financial measures in this manner does not have a standardized meaning prescribed under IFRS Accounting Standards and is therefore unlikely to be comparable to similar financial measures presented by other companies. Onex management believes these financial measures provide useful information to investors. Reconciliations of the non-GAAP financial measures to information contained in the consolidated financial statements have been presented where practical.

Contacts:

Jill Homenuk
Managing Director – Shareholder
Relations and Communications
Tel: +1 416.362.7711Zev Korman
Vice President, Shareholder
Relations and Communications
Tel: +1 416.362.7711

The Tron price has faced pressure in recent days, but a surge in network activity suggests a potential turning point for TRX. While the broader crypto markets remain cautious amid Federal Reserve uncertainty, on-chain data shows record-breaking user engagement on the Tron blockchain.

Ripple-backed startup Evernorth Holdings has emerged as one of the largest institutional holders of XRP, amassing over 388.7 million tokens worth more than $1 billion, according to on-chain data. The move signals a major step toward renewed institutional participation in the XRP ecosystem and could set the stage for wider adoption of Ripple's native asset.

Bitcoin needs a decisive close above $112,926 to confirm short-term bullish continuation.Gold battles resistance near $4,048 amid post-FOMC recovery.Silver’s ascending triangle pattern targets a potential rally to $51.34.After the much-anticipated FOMC interest decision, Bitcoin, the colloquial digital gold, and commodity safe havens like gold and silver seek footing after turbulence.

Markets are moving past policymakers’ decision to cut interest rates by a quarter percentage point to focus on other drivers, including earnings and geopolitics.

Sponsored

Sponsored

What Next for Bitcoin, Gold, and Silver After FOMC Interest Rate Decision?BeInCrypto reported the Fed’s decision to cut interest rates by 25 basis points (bps), effectively ending its balance sheet reduction. The move, which aligned with economists’ expectations, has inspired momentum for Bitcoin, Gold, and Silver prices.

Bitcoin May Only Be Attractive To Buy Past $112,926While policymakers’ decision to cut interest rates is bullish, Bitcoin may only be attractive to buy after crossing $112,926.

A decisive daily candlestick close above this level (the mean threshold or midline) of the supply zone between $111,281 and $114,453 would confirm that bulls have overpowered selling pressure from this order block.

If the Bitcoin price continues to hold above the ascending trendline, such a breach would be inevitable. This trendline has been a longstanding support level for the pioneer crypto since early April.

Bulls waiting for confirmation, however, should consider opening long positions above $114,553. Based on the volume profiles (blue horizontal bars), many bulls are waiting to interact with the BTC price above this level. After all, BTC’s Sharpe Ratio suggests a cycle toward a low-risk period.

Based on the Sharpe Ratio, Bitcoin $BTC tends to cycle between high and low risk periods.

After reaching high-risk territory, a shift toward low risk now looks imminent. pic.twitter.com/9WI1LweQKg

— Ali (@ali_charts) October 30, 2025
The $116,014 level is also critical for the pioneer crypto. It is a support level that has turned resistance and continues to cap further upside. A breach and successful retest of this supplier congestion level could prime BTC price to $120,574.

Sponsored

Sponsored

Nevertheless, the Bitcoin price will have a shot at reclaiming its all-time high above $126,199 when it successfully breaks and closes above $123,917. This level is the midline of the supply zone between $123,094 and $124,630. Such a move would denote an 11.33% move above current levels.

Bitcoin Price Performance. Source: TradingViewConversely, on-chain analyst Ali says the TD sequential signals an imminent sell-off for the Bitcoin price. If the Bitcoin price falls below the ascending trendline, the ensuing selling momentum could see it roll over. It could find immediate support at $106,081.

In a dire case, the downtrend could extend for BTC to collect sell-side liquidity around $102,000, where the October 10 trading session bottomed out.

The MACD (Moving Average Convergence Divergence) is in negative territory, suggesting momentum favors sellers. Similarly, the RSI position below 50 accentuates this outlook.

Sponsored

Sponsored

Until Gold Breaks $4,048, Bears Have the Say!Gold is also attempting a recovery after the FOMC, with the RSI showing rising momentum. However, much remains on the balance because of the overhanging seller congestion levels.

The 9-day SMA (Simple Moving Average) continues to track gold from above at $3,975, limiting its upside potential.

The yellow horizontal bars (bearish volume profiles) also show many sellers waiting to book profits once the gold price reaches between $4,002 and $4,086.

Gold (XAU) Price Performance. Source: TradingViewHowever, a breakout may be imminent, as the gold price is filling up a symmetric triangle on the four-hour timeframe.

In this regard, traders looking to open short positions for the precious metal should consider a decisive candlestick close below $3,917, which could see the XAU price dip toward $3,800. Such a move would constitute a 5% drawdown below current levels.  

Sponsored

Sponsored

This Pattern Could See Silver Price Rise to $51.34Like Bitcoin and gold, silver is also staging a recovery on the one-hour timeframe. However, while it consolidates along an ascending trendline, the resistance level at $48.36 remains a crucial barricade.

The resultant technical formation is an ascending triangle, a bullish continuation pattern that could catapult the silver price 6.20% up to $51.34.

This target objective is determined by measuring the triangle’s height and superimposing it at the expected breakout point. To support this thesis, the bullish profiles (grey horizontal bars) show a large volume of bulls waiting to interact with XAG above the $43.36 roadblock.

Key entry points beyond $43.36 include $48.92 and $49.98, earmarked by the 61.8% and 50% Fibonacci retracement levels, respectively.

Silver (XAG) Price Performance. Source: TradingViewOn the flipside, this bullish technical formation for the silver price could be invalidated if the price falls below $47.41, which coincides with the 78.6% Fibonacci retracement level. A candlestick close below this level on the one-hour timeframe could see XAG price drop toward $45.50, almost 5% below current levels.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Consensys, the Ethereum infrastructure firm best known for building the MetaMask wallet and the Infura developer toolkit, has quietly taken the next formal step toward going public, selecting JPMorgan and Goldman Sachs to lead work on a planned initial public offering, according to Axios. The move places one of the most systemically important companies in the Ethereum ecosystem on a path toward public market scrutiny and capital access after nearly a decade of operating as a privately held, founder-controlled Web3 software company.

Ethereum’s Consensys Gears Up For IPO
The reported bank mandate is the clearest signal so far that Consensys is positioning itself to test US equity markets in the post-2024 regulatory environment, and comes as crypto companies have re-opened the IPO window in 2025 after two years of near-total freeze. Axios reported that JPMorgan and Goldman Sachs have been tapped to run the offering, a role traditionally reserved for deals that are expected to command institutional interest at scale. While neither timeline nor targeted valuation has been formally disclosed, Axios indicated that Consensys is working toward a listing as early as 2026.

Consensys did not confirm an imminent S-1 filing but acknowledged that it is actively evaluating capital markets options. “Consensys is constantly exploring opportunities to expand its impact,” the company told Decrypt when asked about the IPO report. “While we continuously evaluate strategic options for growth, we have nothing to announce at this time.”

A Consensys IPO would be structurally different from the wave of crypto listings that defined the last cycle. Rather than a centralized exchange, a miner, or a pure-play trading proxy, Consensys is an infrastructure and tooling company embedded in Ethereum’s execution layer. The firm develops MetaMask, the self-custody wallet that has, for years, functioned as a default retail access point to Ethereum and EVM-compatible networks, and Infura, the backend service used by hundreds of thousands of developers to route blockchain queries and broadcast transactions without running their own nodes.

MetaMask has been repeatedly described by Consensys as having tens of millions of monthly active users, and Infura processes billions of requests per day for applications that rely on reliable RPC infrastructure. That combination gives Consensys direct exposure to core on-chain activity rather than speculative token price action, which is likely to be a central part of the pitch to public market funds that want revenue tied to Ethereum’s usage rather than just its volatility.

Regulatory posture is a critical part of that story. In February 2025, the US Securities and Exchange Commission informed Consensys that it would move to dismiss its lawsuit over MetaMask’s staking features, walking back allegations that the company had acted as an unregistered broker. The agency’s reversal effectively removed a material overhang on one of Consensys’ most commercially sensitive products, and it did so against the backdrop of a broader softening in crypto enforcement tone under the Trump administration.

Consensys last raised external capital in March 2022, when it closed a $450 million Series D led by ParaFi Capital with participation from Temasek, SoftBank’s Vision Fund 2, Microsoft, and others, valuing the company at roughly $7 billion post-money.

The timing of Consensys’ reported IPO push also lines up with a broader re-entry of crypto names into US public markets in 2025. Stablecoin issuer Circle listed in June at a valuation in the high single-digit billions, while exchange operator Bullish won a New York Stock Exchange listing in August.

At press time, ETH traded at $3,907.

ETH slips below the 0.786 Fib again, 1-week chart | Source: ETHUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Jake Simmons has been a Bitcoin enthusiast since 2016. Ever since he heard about Bitcoin, he has been studying the topic every day and trying to share his knowledge with others. His goal is to contribute to Bitcoin's financial revolution, which will replace the fiat money system. Besides BTC and crypto, Jake studied Business Informatics at a university. After graduation in 2017, he has been working in the blockchain and crypto sector. You can follow Jake on Twitter at @realJakeSimmons.

The site aims to provide clear guidance for organizations entering the blockchain space while showcasing real-world progress from companies already using Ethereum to power finance on the internet. Ethereum's message is clear: the network is becoming the base layer for global finance, secured by more than 1.

At the recent Future Investment Initiative (FII) event in Riyadh, Saudi Arabia, some of the biggest names in crypto gathered to talk about where the industry is heading. The panel, hosted by Fundstrat’s Tom Lee, included Jeremy Allaire, Saifedean Ammous, Ricardo B. Salinas Pliego, and Ripple CEO Brad Garlinghouse.

During the discussion, Garlinghouse sounded confident about the road ahead for digital assets. He said the next sixteen years will likely be even better than the last, as crypto moves past speculation and starts finding real, everyday uses in finance and technology.

Garlinhouse’s Confidence in the Future of Crypto During the event held from October 27 to 30, 2025, Brad Garlinghouse and economist Saifedean Ammous exchanged their views on the future of crypto. Ammous argued that there is still no global consensus on how digital assets should evolve.

Garlinghouse agreed, saying crypto remains in its early phase since no single approach or framework dominates the space yet. He highlighted that companies like Circle are beginning to show real-world use cases, especially with stablecoins, marking progress toward practical adoption.

He added that the next sixteen years will be about growth and real utility, as crypto shifts from being mainly about value storage or speculation to powering meaningful, everyday applications.

“The next 16 years, I think, will be better than the last 16 years because you’ll finally see applications emerging that up until now have just been the store of value, story, or speculation,” Garlinghouse said. 

Bitcoin is Digital GoldAmmous explained that Bitcoin is like digital gold, but better for today’s global economy because crypto is easier to use for payments. Since the world economy relies on moving money fast, across borders, gold physically cannot keep up, and also politically sensitive because gold is centralized. 

He said, “Most businesses deal across International borders, and they need their money to move. And you know, when the digital economy money’s speed is increasing more and more, and therefore gold is physically cannot keep up physically because I think it’s too politically centralized and politically sensitive.” 

He also pointed out that Bitcoin is faster and more practical for moving money globally and directly without needing banks to clear payments. This is why Bitcoin has grown so much more than gold in value in the past sixteen years, and Ammous expects this trend to continue.  

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

With over four years of experience in covering and tracking the financial markets, Sneha Agrawal is a dedicated Crypto Journalist and Editor with passion for researching and writing the crypto pieces. She is currently leading the Block of Fame, here at CoinGape. She likes to keep track of political, legal and financial happenings all around the world - without which she deems her day incomplete. Apart from her Journalistic endeavours, she is a solo traveler, museum goer, and a keen reader of books.

Grayscale Investments kicked off trading of a new Solana-focused ETF on Wednesday, adding a staking feature that passes network rewards to investors.

The fund, now listed on NYSE Arca as the Grayscale Solana Trust ETF (GSOL), was converted from a closed-end vehicle that first launched in 2021.

From Closed-End Trust To ETF
According to Grayscale, the move makes the firm one of the largest Solana exchange-traded product managers in the US by assets under management.

The converted ETF lets ordinary brokerage accounts hold SOL exposure while receiving staking rewards tied to the network.

Inkoo Kang, Grayscale’s Senior Vice President of ETFs, said the launch shows the firm’s belief that digital assets should sit alongside stocks and bonds in modern portfolios.

Introducing Grayscale Solana Trust ETF (Ticker: $GSOL), offering investors exposure to @Solana $SOL, one of the fastest-growing digital assets. $GSOL features:

⚡ Convenient Solana exposure paired with staking benefits.

🔑 Exposure to a high-speed, low-cost blockchain.… pic.twitter.com/TgVNlhqBPO

— Grayscale (@Grayscale) October 29, 2025

Competition Increased This Week
Based on reports, Grayscale is not alone. Bitwise rolled out its own Solana ETF on the New York Stock Exchange one day earlier. Canary also listed Litecoin and HBAR ETFs on Nasdaq on Tuesday.

Those moves came amid strong interest from asset managers to offer regulated crypto funds that give investors straightforward access to tokens without direct custody.

🚨JUST IN: $GSOL, the first Grayscale Solana Trust ETF with staking, goes live on @NYSE Arca, offering U.S. investors spot @Solana exposure and staking rewards under newly approved SEC listing standards. pic.twitter.com/eTzVP9Kb1X

— SolanaFloor (@SolanaFloor) October 29, 2025

Regulatory Timing And Guidance
These ETF launches happened while the US government was partially shut down and some SEC staff were furloughed.

Kristin Smith, president of the Solana Policy Institute, said staking-enabled funds offer more than simple price exposure; participants can help secure the network, support developer work, and earn rewards.

The Securities and Exchange Commission issued guidance permitting firms to file S-1 registration statements without a delaying amendment, which lets certain funds take effect automatically within 20 days of filing.

The SEC had also approved updated listing standards for commodity-based trust shares shortly before the staffing disruption, a step that helped speed up approvals for dozens of pending crypto ETF applications.

SOL market cap currently at $106 billion. Chart: TradingView
What This Means For Solana Holders
Solana has consistently cemented its status among the powerhouse tokens in terms of market valuation, taking the sixth spot, according to CoinMarketCap.

Based on reports, the new listings did not include full details on fee levels, which validators will be used for staking, or how staking rewards will be split after expenses.

Those operational questions matter to investors weighing net returns and counterparty risk. Trading on NYSE Arca does mean easier access through brokerages, but the finer points of how staking is run will shape how attractive GSOL becomes versus other Solana products.

Featured image from Gemini, chart from TradingView